Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.72), $0.14 better than the analyst estimate of ($1.86). Revenue for the quarter came in at $21.58 million versus the consensus estimate of $17.25 million.

"In recent months, we made significant progress toward achieving our key 2021 portfolio goals, illustrating our clinical leadership in systemic mastocytosis and the rapid advancement of our next wave of therapeutic candidates with first- or best-in-class potential," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "With a potential U.S. approval for AYVAKIT in advanced systemic mastocytosis in the second quarter, we are looking forward to welcoming a new era of precision medicines care for people living with this debilitating disease. In parallel, we are initiating multiple clinical trials across our pipeline, beginning with the Phase 1 trial of BLU-945 and Phase 2/3 HARBOR trial of BLU-263, as we continue to translate our research productivity and precision therapy expertise to address patient need across cancers and hematologic malignancies. Taken together, these accomplishments position Blueprint Medicines to help an increasing number of patients globally as we advance our robust portfolio."

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.